Patrick Lucy
Chairman at DYADIC INTERNATIONAL, INC.
Net worth: 40 489 $ as of 30/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Mark Emalfarb | M | 69 | 45 years | |
Ping Rawson | M | 48 | 8 years | |
Charles Berkman | M | 55 | 4 years | |
Michael Tarnok | M | 69 | 10 years | |
Arindam Bose | M | 71 | 8 years | |
Joseph Hazelton | M | 48 | 3 years | |
Janet Downie | F | - |
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | - |
Andrea Ponti | F | 61 |
Lykan Bioscience LLC
Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA.
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | - |
Jack Kaye | M | 80 | 9 years | |
Seth Herbst | M | 66 | 16 years | |
Barry Buckland | M | 76 | 6 years | |
CHRISTOPHER C PETRINI | M | - |
Lykan Bioscience LLC
Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA. | - |
Matthew Foehr | M | 51 | 4 years | |
Kelly O'Hare | F | - |
Lykan Bioscience LLC
Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA. | - |
Alan Mackay | M | - |
Lykan Bioscience LLC
Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA. | - |
Keith Haney | M | - | 10 years | |
Dean Morris | M | - |
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | 1 years |
Geoffrey Hamilton-Fairley | M | - |
Lykan Bioscience LLC
Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA. | - |
Christopher Burnes | M | - |
Lykan Bioscience LLC
Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA. | - |
Matthew Korenberg | M | 49 | 4 years | |
Ronen Tchelet | M | 66 | 10 years | |
Geoffrey Neil Hamilton-Fairley | M | 63 |
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | - |
Ian McCubbin | M | 68 |
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | - |
Alan Browning MacKay | M | 62 |
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | - |
John Higgins | M | 54 | 4 years | |
Peter J. Crowley | M | 65 |
Lykan Bioscience LLC
Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA. | - |
Doug Pace | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Walter C. Herlihy | M | 72 | 32 years | |
Evert Schimmelpennink | M | 52 | 3 years | |
Bertrand C. Liang | M | 61 | 8 years | |
Sandy Smith | M | 77 | 10 years | |
William R. Rohn | M | 80 | 3 years | |
John M. Taylor | M | 59 | 5 years | |
Lorianne K. Masuoka | M | 62 | 1 years | |
Jason Grenfell-Gardner | M | 49 | 3 years | |
Patricia Lady | F | 65 | - | |
Dennis Fenton | M | 72 | 4 years | |
Robin D. Campbell | M | 69 | 6 years | |
Sigurdur Olafsson | M | 55 | 2 years | |
Magda Marquet | M | 65 | 1 years | |
Matthew S. Jones | M | 47 | 6 years | |
Phillip Schneider | M | 67 | 6 years | |
James Gale | M | 74 | - | |
Daniel P. Witt | M | 76 | 29 years | |
Henry W. Talbot | M | 72 | - | |
Kenneth van Heel | M | 60 | - | |
Howard Levine | M | - | 3 years | |
Steven S. Sandoval | M | - | 1 years | |
Martin Brenner | M | 54 | 1 years | |
Susan Lowther | F | 65 |
Lonza Biologics Plc
Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | 1 years |
Hubert Chen | M | 55 | 4 years | |
Paul Wagner | M | 53 | 3 years | |
Shawn A. Scranton | M | 60 | 2 years | |
Susan Dexter | F | 67 |
Lonza Biologics Plc
Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | 12 years |
Susan Knudson | F | 60 | 1 years | |
Mark F. Boshar | M | - | 3 years | |
James R. Rusche | M | 69 | 20 years | |
Avery Catlin | M | 75 | 4 years | |
Modestus Obochi | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 52 | 88.14% |
United Kingdom | 8 | 13.56% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Patrick Lucy
- Personal Network